$14.99
-0.17[-1.12%]
At close: Apr 25
$14.99
0[0.00%]
After Hours: 4:20PM EDT
Innoviva
(NASDAQ:INVA)Latest News for Innoviva Stock (NASDAQ:INVA)
Innoviva Stock (NASDAQ: INVA)
Categories: All
Friday, March 08, 2024
Monday, March 04, 2024
Thursday, February 29, 2024
Wednesday, November 01, 2023
- Innoviva Q3 EPS $0.98, Sales $67.26M Miss $75.65M EstimateBenzinga Newsdesk - Nov 1, 2023, 5:39PM
- Innoviva Q3 EPS $0.98 May Not Compare To $0.27 Estimate, Sales $67.26M Miss $75.65M EstimateBenzinga Newsdesk - Nov 1, 2023, 5:38PM
- The Global Antibiotic Research & Development Partnership, In Collaboration With Innoviva Specialty Therapeutics, Subsidiary Of Innoviva Announced Results In Largest Pivotal Phase 3 Trial Of A First-In-Class Oral Antibiotic To Treat Uncomplicated GonorrheaBenzinga Newsdesk - Nov 1, 2023, 5:37PM
Monday, October 02, 2023
Monday, September 18, 2023
Friday, September 01, 2023
Thursday, August 03, 2023
Wednesday, August 02, 2023
Monday, July 31, 2023
Wednesday, May 24, 2023
Tuesday, May 16, 2023
Monday, May 15, 2023
Wednesday, May 10, 2023
Tuesday, May 09, 2023
Monday, May 08, 2023
Thursday, April 20, 2023
Tuesday, April 18, 2023
- Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top StoriesVandana Singh - Apr 18, 2023, 9:30AM
- FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial InfectionsVandana Singh - Apr 18, 2023, 9:22AM
Monday, April 17, 2023
- Innoviva Shares Resume TradeMichael Horton - Apr 17, 2023, 5:01PM
- Innoviva Announces The FDA Voted In Support Of Approval Based On Risk-Benefit Assessment Of Sulbactam-DurlobactamBenzinga Newsdesk - Apr 17, 2023, 4:32PM
- Innoviva Stock Trading Halted Today; FDA Advisory Committee To Review Sulbactam-Durlobactam For The Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia Caused By Susceptible Strains Of AcinetobacterHappy Mohamed - Apr 17, 2023, 9:09AM
- Innoviva Shares Halted, News PendingHappy Mohamed - Apr 17, 2023, 8:55AM
Tuesday, March 14, 2023
Friday, March 10, 2023
Friday, March 03, 2023
- What 4 Analyst Ratings Have To Say About InnovivaBenzinga Insights - Mar 3, 2023, 4:01PM
- Goldman Sachs Maintains Neutral on Innoviva, Lowers Price Target to $13Benzinga Newsdesk - Mar 3, 2023, 10:45AM
- Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $10Benzinga Newsdesk - Mar 3, 2023, 9:38AM
- EF Hutton Reiterates Buy on Innoviva, Maintains $22.5 Price TargetBenzinga Newsdesk - Mar 3, 2023, 9:15AM